Levofloxacina Hikma (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes that control DNA supercoiling and replication. By preventing these enzymes from functioning, the drug stops bacterial DNA synthesis and transcription, leading to bacterial cell death and resolution of the infection.

The dose of Levofloxacina Hikma is set by the prescribing clinician based on the type and severity of infection, the patient’s renal function, weight, and any relevant comorbidities. No fixed regimen is provided here; the prescriber tailors therapy to each individual case.

Levofloxacina Hikma falls under an unknown pregnancy category, and safety data are limited. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levofloxacina Hikma contains levofloxacin, the L‑isomer of ofloxacin, offering higher potency and better tissue penetration than many older fluoroquinolones. It provides a broader spectrum against Gram‑negative organisms and is often preferred for severe infections requiring intravenous therapy, though safety considerations remain similar across the class.

Levofloxacina Hikma should be stored at temperatures below 25 °C, protected from light and moisture. Keep the product in its original packaging until use and avoid exposing it to extreme heat or humidity to maintain stability and potency.

Levofloxacina Hikma is administered intravenously by a healthcare professional. The infusion is typically given over a set period as directed by the prescriber, using aseptic technique and appropriate IV equipment. Administration details, including infusion rate, are determined by the treating clinician.

Serious risks include tendon rupture or tendinitis, QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for these events.

Levofloxacina Hikma should be avoided in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with significant QT prolongation, and patients with uncontrolled epilepsy. Clinical judgment is required for all other contraindications.